1. Home
  2. AACG vs SCLX Comparison

AACG vs SCLX Comparison

Compare AACG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AACG

ATA Creativity Global

HOLD

Current Price

$0.93

Market Cap

51.0M

Sector

Real Estate

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$7.11

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AACG
SCLX
Founded
1999
2011
Country
China
United States
Employees
N/A
34
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
52.5M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
AACG
SCLX
Price
$0.93
$7.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.3K
98.1K
Earning Date
05-15-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$4.20
52 Week High
$2.58
$34.27

Technical Indicators

Market Signals
Indicator
AACG
SCLX
Relative Strength Index (RSI) 36.26 48.13
Support Level $0.85 $5.72
Resistance Level $1.08 $7.77
Average True Range (ATR) 0.08 0.86
MACD -0.01 -0.06
Stochastic Oscillator 20.00 42.32

Price Performance

Historical Comparison
AACG
SCLX

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: